This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements
include but are not limited to statements regarding the further development
and potential safety, efficacy, regulatory status, commercial potential and
other characteristics of Kosan's product candidates; the continuation of
current clinical trials; the initiation of additional clinical trials and
the timing thereof and the use of Kosan's financial resources. Words such
as "will," "expect," "believe," "may," "intend," "plan," "potential" and
similar expressions are intended to identify forward-looking statements.
Any statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. These
forward-looking statements are based upon Kosan's current expectations.
Forward-looking statements involve risks and uncertainties. Kosan's actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, risks related
|SOURCE Kosan Biosciences Incorporated|
Copyright©2008 PR Newswire.
All rights reserved